H. Tran

ERCC5 is a novel biomarker of ovarian cancer prognosis.

Carl W. Miller, B. Karlan, S. Ogawa, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis.

R. L. Baldwin, B. Karlan, H. Tran, 1999, Gynecologic oncology.

BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.

R. L. Baldwin, B. Karlan, S. Narod, 2000, Cancer research.

Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables.

J. Heine, G. Sica, F. Khuri, 2013, Clinical lung cancer.

Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening.

B. Karlan, R. Alsabeh, H. Koeffler, 2010, Gynecologic oncology.

BRCA 1 Promoter Region Hypermethylation in Ovarian Carcinoma : A Population-based Study 1

R. L. Baldwin, B. Karlan, S. Narod, 2000 .

Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT.

Daniel R. Scoles, R. L. Baldwin, B. Karlan, 2007, Gynecologic oncology.

Multidrug Combinations for First-line Therapy of Advanced Non-small-cell Lung Cancer

S. Ramalingam, H. Tran, 2011 .

Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein.

Daniel R. Scoles, B. Karlan, D. Scoles, 2010, Gynecologic oncology.

Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.

Beth Y Karlan, R. L. Baldwin, Rae Lynn Baldwin, 2003, Cancer research.

ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma.

B. Karlan, S. Orsulic, J. Lester, 2015, Carcinogenesis.